ANN ARBOR — A new study by researchers from the University of Michigan, Yale School of Public Health, Brown University and Ann Arbor-based Compendia Bioscience provided a comprehensive genomic profiling of patients with pre-treated lethal metastatic prostate cancer, providing insights into mechanisms of resistance.
The study, published in the scientific journal Nature, identified a diverse series of likely driving mutations and copy number alterations in both known and novel genes. Oncomine streamlined analysis of genome alterations and provided a platform for rapid validation across previously published studies.
“The Oncomine tool set was developed to mine the global collection of cancer genomic data – our most recent advances focusing on mutation and copy number analysis. It is always rewarding to see our platform contributing to scientific discovery,” said Dr. Daniel Rhodes, CEO of Compendia Bioscience.
Integrated analysis of copy number and mutation data identified loss of CHD1, a chromatin-modifying enzyme, as a key genetic event in ETS-negative prostate cancer. With Oncomine, the team was able to rapidly validate this observation across 13 independent, previously published patient cohorts.
“Oncomine continues to be my go-to reference database to analyze and validate cancer genomic findings,” said Dr. Scott Tomlins, senior author of the study. “The latest advances in mutation and copy number analysis are quite powerful and the ability to quickly and easily compare multiple data sets is unmatched.”
Compendia Bioscience is dedicated to curing cancers through the application of genomic data by providing researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. Visit www.compendiabio.com for more information.
Oncomine combines a rapidly growing compendium of more than 62,000 expertly curated cancer genomic profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. Visit www.oncomine.com for more information.
More at www.compendiabio.com.